A Phase IIb, Prospective, Intra-patient Randomised Controlled, Multicentre Study to Evaluate the Safety and Efficacy of an Autologous Bio-engineered Dermo-epidermal Skin Substitute (EHSG-KF) for the Treatment of Partial Deep Dermal and Full Thickness Burns in Adults and Adolescents in Comparison to Autologous Split-thickness Skin Grafts (STSG)
Latest Information Update: 16 Jan 2025
At a glance
- Drugs EHSG-KF (Primary)
- Indications Burns
- Focus Therapeutic Use
- Sponsors CUTISS
Most Recent Events
- 13 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2025 Planned End Date changed to 31 Aug 2025.
- 07 Dec 2023 New trial record